A complete evaluation of respiratory health involves a range of tests, collectively known as Pulmonary function testing (PFT). The global lung function testers market, valued at USD 2.0 billion in 2025 and projected to grow to USD 3.0 billion by 2035, reflects the importance of these comprehensive assessments in diagnosing and managing a wide spectrum of respiratory disorders.

Pulmonary function testing encompasses a variety of non-invasive tests that measure how well the lungs are working. In addition to spirometry, PFT includes tests such as lung volume measurement (using body plethysmography or gas dilution), diffusing capacity of the lungs for carbon monoxide (DLCO), and peak flow measurement. These tests provide a comprehensive picture of lung function, including how much air the lungs can hold, how well they move air in and out, and how efficiently they transfer oxygen to the blood. PFT is essential for diagnosing and differentiating between various lung diseases, including obstructive diseases like COPD and asthma, and restrictive diseases like pulmonary fibrosis.

The Components of a Comprehensive PFT

A comprehensive pulmonary function test typically includes several components. Spirometry is the core test, measuring airflow. Body plethysmography measures lung volumes, including Total Lung Capacity (TLC) and Residual Volume (RV). The DLCO test measures the gas exchange function of the lungs. Pulse oximetry measures oxygen saturation. The specific tests performed depend on the patient's symptoms and the clinical question. The results of PFT are interpreted by a specialist, often a pulmonologist, who uses them to make a diagnosis and guide treatment. The integration of PFT with other diagnostic tools, such as imaging and blood tests, provides a comprehensive assessment of respiratory health.

Market Trends and Future of PFT

The market for pulmonary function testing is being shaped by the demand for more accurate, efficient, and accessible testing. The development of more portable and user-friendly devices is expanding access to PFT in diverse settings. The integration of digital technology and artificial intelligence is enabling more sophisticated data analysis and interpretation. The focus on remote patient monitoring is driving the development of home-based PFT devices. As the global burden of respiratory diseases continues to rise, the role of Pulmonary function testing in diagnosing and managing these conditions will remain essential.